Compare Gitlab Inc (GTLB) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Gitlab Inc trades at $55.09 (market cap $8.92B), while Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 8.5× Gitlab Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gitlab Inc for 62 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| GTLB | REGN | |
|---|---|---|
Market Cap | $8.92B | $76.14B |
Volume | 4,716,893 | 500,239 |
Sector | Technology | Health |
52-Week High | $53.56 | $852.03 |
52-Week Low | $19.42 | $557.73 |
Typical Hold Time | 62 Days | 107 Days |
Enterprise Value | $7.66B | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $53.56, up 3.02% today and near its 52-week high, with strong technical momentum indicated by moving averages. The company shows impressive revenue growth, reaching $759 million in 2025, but remains unprofitable with a negative net income margin of -4.99%. Recent Q2 2026 earnings beat expectations, and the stock surged on raised guidance and AI-driven demand optimism.
Outlook: GitLab benefits from AI integration in software development and strong sales momentum, but high valuation multiples (P/E 521) and persistent losses pose risks. Analyst consensus is mixed with a $49.71 price target below current levels, suggesting cautious optimism amid execution challenges and competitive pressures.
Regeneron Pharmaceuticals (REGN) trades at $739.57, down 0.34% with a bearish technical signal. The company maintains strong fundamentals with a 27.86% net income margin and consistent earnings beats. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront payments and milestone potential. Cash flow improved significantly in 2025 with $635 million net cash flow versus negative flows in prior years.
The stock presents a compelling investment case with strong profitability, positive analyst sentiment (69% buy ratings), and a $849.84 consensus price target offering 15% upside. Key risks include competitive pressures in ophthalmology drugs and reliance on key partnerships. The expanded Sanofi collaboration and promising clinical pipeline provide catalysts for growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
